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The aim of the study was to determine the dose-limiting toxicity and maximum tolerated dose of a first-line combination of
doxorubicin and gemcitabine in adult patients with advanced soft tissue sarcomas and to explore its activity and toxicity, and the
presence of possible interactions between these agents. Patients with measurable disease were initially treated with doxorubicin
60mgm
 2 by i.v. bolus on day 1 followed by gemcitabine at 800mgm
 2 over 80min on days 1 and 8, every 21 days. Concentrations
of gemcitabine and 20,20-difluorodeoxyuridine in plasma, and gemcitabine triphosphate levels in peripheral blood mononuclear cells
were determined during 8h after the start of gemcitabine infusion. Myelosuppression and stomatitis were limiting toxicities, and the
initial dose level was applied for the Phase II trial, where grade 3–4 granulocytopenia occurred in 70% of patients, grade 3 stomatitis
in 46% and febrile neutropenia in 20%. Objective activity in 36 patients was 22% (95% CI: 9–35%), and a 50% remission rate was
noted in leiomyosarcomas. Administration of doxorubicin preceding gemcitabine significantly reduced the synthesis of gemcitabine
triphosphate. Clinical activity, similar to that of single-agent doxorubicin, and the toxicity encountered do not justify further studies
with this schedule of administration.
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Doxorubicin (DXR) and ifosfamide are the only two drugs with
consistent activity against advanced soft tissue sarcoma (ASTS) of
the adult and constitute the backbone of combinations to treat this
group of diseases. However, as overall efficacy of chemotherapy in
ASTS is limited, new approaches are needed to improve
therapeutic results (Brennan et al, 2001, p 1841). Among new
agents, gemcitabine has shown some efficacy either as first-line or
in those patients refractory to DXR and ifosfamide, with an activity
that varies from 3 to 18% (Amodio et al, 1999; Merimsky et al,
2000; Spath-Schwalbe et al, 2000; Patel et al, 2001; Svancarova et al,
2002; Okuno et al, 2003). Therefore, we decided to explore the
activity of a combination of DXR and gemcitabine.
Gemcitabine has to be phosphorylated to its diphosphate and
triphosphate (dFdCTP) forms to exert its biologic effects, and it is
deaminated to generate 20,20-difluorodeoxyuridine (dFdU), which
would be devoid of antitumour activity (Plunkett et al, 1995).
Intracellular accumulation of dFdCTP by peripheral blood mono-
nuclear cells (PBMCs) is optimal when gemcitabine is delivered at
a fixed dose-rate (FDR) infusion of 10mgm
 2min
 1 (Abbruzzese
et al, 1991; Grunewald et al, 1991). The recommended dose for
FDR infusion gemcitabine is 1500mgm
 2 for 3 out of 4
consecutive weeks (Brand et al, 1997; Touroutoglou et al, 1998).
Gemcitabine and DXR had been combined to treat patients with
advanced breast carcinoma in a study where both agents were
given for 3 out of 4 consecutive weeks, with median tolerated doses
of 800mgm
 2 for gemcitabine and 20mgm
 2 for DXR (Pe ´rez-
Manga et al, 2000). Because DXR with FDR infusion gemcitabine
had not been given before, we performed a Phase I trial to
determine the dose-limiting toxicity (DLT) and the recommended
dose for subsequent studies. Initial doses were DXR 60mgm
 2 on
day 1, followed by gemcitabine 800mgm
 2 on days 1 and 8. This
study was followed by a Phase II trial to evaluate the activity and
obtain additional information on the toxicity of this regimen.
Another objective was to detect possible interactions between DXR
and gemcitabine.
MATERIALS AND METHODS
Patients
Eligible patients should have an histologic diagnosis of ASTS, with
local or advanced unresectable and measurable disease, no prior
chemotherapy, performance status p2 (WHO), adequate bone
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smarrow (leucocytes X3.0 10
9l
 1, granulocytes X1.5 10
9l
 1,
platelets X100 10
9l
 1), liver (bilirubin p1.5-fold and AST and
ALT o2.5-fold upper normal limits) and renal (creatinine
p1.5mgdl
 1) functions and left ventricular ejection fraction
(LVEF) X50%. Patients o18 years old, with severe associated
diseases or active infection, CNS metastases, NYHA cardiac disease
of grade 42 were excluded. Spanish Ministry of Health and Ethics
Committee of all participating institutions approved the study, and
informed patients signed a consent form.
Treatment and study design
Patients received DXR and gemcitabine every 3 weeks. The dose
level of DXR was fixed at 60mgm
 2 and dose levels for
gemcitabine in the Phase I were 800 (dose level 1), 1000 (dose
level 2) and 1200mgm
 2 (dose level 3). On day 1, DXR was
delivered by i.v. bolus, immediately followed by gemcitabine
(10mgm
 2min
 1), and on day 8 the dose of gemcitabine was
repeated. Three new patients were entered at each dose level. If
DLT was encountered in one of three patients, three additional
patients were entered at that dose level, and if two patients had
DLT at a particular dose level, this would represent the maximum
tolerated dose (MTD), and the prior level would be applied in the
Phase II study. Dose-limiting toxicity was the presence of febrile
neutropenia, grade 4 neutropenia or thrombocytopenia lasting
more than 4 days, grade 3 thrombocytopenia with bleeding, any
grade 3–4 non-haematologic toxicity (except for nausea and
vomiting) or cardiac toxicity X grade 2. Antiemesis consisted of
anti-HT3 plus dexamethasone, with dexamethasone omitted in
patients participating in the pharmacokinetic study.
Toxicity
Toxicity was evaluated according to the NCI Common Toxicity
Criteria, Version 1.0. Cycles were delivered on schedule if
granulocytes X1.5 10
9l
 1 and platelets X100 10
9l
 1, and no
grade 3–4 non-haematologic toxicity were present. In other
situations, the treatment was delayed, and if no recovery had
occurred within 3 weeks the patient was removed from the study. If
a patient had DLT in the previous cycle or a 2-week delay was
necessary, the dose of both DXR and gemcitabine was reduced by
25%. Patients with more than two dose reductions abandoned the
study. On day 8, the dose of gemcitabine was reduced by 25% with
granulocytes 500–1000 10
9l
 1 and/or platelets 50–100 10
9l
 1,
and omitted if granulocytes o500 10
9l
 1 and/or platelets
o50 10
9l
 1. Both DXR and gemcitabine doses were reduced
by 25 or 50%, respectively, in the presence of any non-
haematologic toxicity of grade 3 or 4. If any toxicity grade 3–4
recurred after a dose reduction, the patient was retired from the
study. A maximum of six cycles were established per protocol.
Study parameters and criteria of response
Patients were controlled weekly during the Phase I to check
analytical and general toxicity. The LVEF was determined every
other cycle during the Phase I study, and at the end of treatment in
the Phase II study. During Phase II, analytical monitoring was
performed on days 1, 8 and 21. All patients receiving at least one
cycle of therapy were considered evaluable for toxicity. The first
evaluation of activity was performed after two cycles or 6 weeks on
study. Target lesions were measured every 6 weeks or whenever
progressive disease was suspected, applying RECIST criteria for
efficacy (Therasse et al, 2000), and objective remissions were ex-
ternally reviewed. The duration of overall response was measured
from the day it was first detected until the date of progression.
Time to progression was the time elapsed from inclusion until
detection of progressive disease. Progression-free rate was the
proportion of patients without progression at a given time.
The dose intensity per patient was calculated by dividing total
dose given (mgm
 2) by the time elapsed from the first to the last
dose plus 3 additional weeks. Relative dose intensity was the ratio
of received to projected dose intensity.
Pharmacokinetic analysis
On days 1 and 8 of the same cycle, blood samples were collected in
heparinised tubes containing tetrahydrouridine. Samples were
obtained at baseline, at 30 and 45min, just before completion of
infusion and hourly during 8h. Samples were placed on ice,
centrifuged and plasma stored at  261C. Peripheral blood
mononuclear cells were obtained through a Ficoll–Hypaque
gradient, and isolated cells were preserved at  701C. Gemcitabine
and dFdU plasma concentrations and dFdCTP levels in PBMCs
were determined by reverse-phase HPLC, according to published
methods (Losa et al, 2004, 2005). The lower limits of quantification
for gemcitabine and dFdCTP were, respectively, 0.36 and
0.174mgml
 1.
Gemcitabine concentration at steady state (Css) was the mean of
values after equilibrium was reached. Cmax was the highest
concentration detected for dFdU and dFdCTP. The area under
the concentration–time curve (AUC0 8h) for gemcitabine, dFdU
and dFdCTP was obtained by applying the linear trapezoidal rule
from time 0 until 8h from start of gemcitabine infusion. AUCinf
was the accumulation of dFdCTP in PBMCs during gemcitabine
infusion. Total body clearance (Cl) for gemcitabine was obtained
from the relation dose/AUC. The half-life and the apparent volume
of distribution of gemcitabine (Vd¼Cl/k, where k is the
elimination constant for gemcitabine) were estimated only in
patients with adequate infusional or postinfusional data.
Plasma concentrations of DXR and doxorubicinol (DOL) were
determined according to a published method (Maessen et al, 1988)
with slight modifications following the introduction of dauno-
rubicin as an internal standard, which allowed us to fully validate
the method. AUC1 8h of both DXR and DOL was estimated by
applying the log-linear trapezoidal rule. These data, linearly
corrected for a dose of 50mgm
 2, were compared with those of
a series of 16 patients treated with DXR at 50mgm
 2 delivered by
i.v. bolus, previously studied in our laboratory. In these historical
controls, AUC0 N for DXR was 23927556nMh, Cl 62715lh
 1
and terminal elimination half-life 35.7711.5h (mean7s.d.).
Statistics
Sample size for the Phase II trial was calculated according to the
two-stage optimal design of Simon (1989), with a¼0.10, b¼0.10,
P0¼20% and P1¼40%. If less than three remissions occurred in
the first 17 patients, the study should be interrupted because
objective activity would be lower than 20%. If p10 partial
remissions were observed in 37 evaluable patients, the schedule
would have an activity lower than 40%, and will not be considered
for further development. The study continued after the positive
results of the first step, but it was closed because only eight
objective remissions were observed in 36 fully assessable patients.
Mean7s.d. of the different pharmacokinetic parameters was
determined, and data on day 8 were pair-compared with those on
day 1 by the Wilcoxon signed ranks test. The values for DXR and
DOL were compared with historical data with the Student’s t-test.
All P-values presented are two-sided.
RESULTS
Phase I trial
From September 2001 to June 2002, 11 patients were included
(Table 1) and the toxicity of the first cycle was considered to
determine the MTD. Of the first three patients treated at dose level
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s1, one had haematologic DLT and died of septic shock after
haematologic recovery, whereas another referred asthenia grade 2.
In the next three patients treated at dose level 1, one episode of
stomatitis grade 3 and one episode of grade 2 asthenia were
observed. At this stage, with two out of six patients showing DLT
and a rather low dose of gemcitabine, we decided to confirm that
dose level 1 represented in fact the MTD. Therefore, three more
patients were included at dose level 1 without observing further
episodes of DLT. Then, dose Level 2 was explored, with two out of
two patients presenting DLT. The first patient had grade 3
stomatitis and febrile neutropenia, without haematologic recovery
by day 21; the second patient had grade 4 neutropenia lasting more
than 7 days. The Phase II study was thus conducted at DXR
60mgm
 2 on day 1 and gemcitabine 800mgm
 2 on days 1 and 8,
every 3 weeks. The toxicity of the 30 cycles (median 3, range 1–6)
received by nine Phase I patients treated at the recommended dose
is presented combined with that of Phase II patients. In nine
patients assessable for efficacy, two partial remissions (one patient
with a uterine leiomyosarcoma and one patient with an
unclassified sarcoma of the limb), three stabilisations and four
progressions were noted.
Phase II trial
From July 2002 to December 2003, 40 patients were enrolled, and
four ineligible patients (one adenocarcinoma, one extraskeletal
myxoid chondrosarcoma and two gastrointestinal stromal tu-
mours) were excluded from any analysis. Thirty-six patients
(Table 1) were valid for activity and one was not assessable for
haematologic toxicity. A total of 162 cycles were delivered with a
median of 4.5 cycles (range 1–9) per patient. Two patients received
only one cycle due to progressive disease.
Toxicity
In Table 2, we present the haematologic toxicity observed in 192
cycles and 44 patients. The nadir and recovery of granulocytes
occurred on days 13 (5–35) and 21 (14–33), respectively (mean,
range). Packed red blood cells were required by 18 patients in 28
cycles, and platelets were transfused to one patient in one cycle.
One patient presented a haemoglobin value of 6.8gdl
 1 after
tumour bleeding. Non-haematologic toxicity is presented in
Table 3.
Grade 2 increase of ALT values was noted in 9% of patients, and
grade 2 and 3 increase in g-glutamyl transferase values occurred in
9 and 4%, respectively. Alopecia was universal. Other toxic effects
noted were fever grade 1 (four patients), erythema plus pruritus
(two) or repeated episodes of conjunctivitis (one). Febrile
neutropenia occurred in 10 patients and 20 cycles; only two of
those episodes were noted among 14 patients receiving gemcita-
bine on day 8 with granulocytes 500–1000 10
9l
 1. Sixteen
patients in 21 cycles required admission to hospital for treatment-
related side effects. Ten patients, including three Phase I patients,
had excessive toxicity consisting of grade 3 stomatitis plus grade
3–4 haematologic toxicity (four), myelosuppression that required
successive dose reductions (three), a decrease in LVEF to 45%
(one), interstitial pneumonitis (one) or grade 3 asthenia plus
severe infection (one), which led to premature interruption of
therapy.
Dose intensity
The dose of DXR was reduced in 27% of cycles, and that of
gemcitabine in 40%, whereas 12% of cycles were delayed, usually
owing to lack of haematologic recovery or persistent stomatitis.
The dose of gemcitabine on day 1 was reduced in 32% of cycles,
and that of day 8 in 35%, this dose being held in 8% of cycles.
Median dose intensities of DXR and gemcitabine were, respec-
tively, 18.2mgm
 2week
 1 (range 13–21) and 436mgm
 2week
 1
(range 243–562mgm
 2week
 1), with a relative dose intensity of
89711% for DXR and 82715% for gemcitabine (mean7s.d.).
Response to therapy and clinical evolution
In 36 patients, one complete and seven partial remissions, 18
stabilisations and 10 progressions were noted (22% response rate;
Table 1 Patient characteristics
Phase I Phase II
Number 11 36
Male/female 5/6 20/16
Age (median, range) 51 (35–69) 59 (23–80)
Performance status
03 7
14 2 5
24 4
Histologic type of sarcoma
Liposarcoma 3 9
Leiomyosarcoma 2 6
Malignant fibrous histiocytoma — 4
Angiosarcoma 1 2
Other or unclassified 5 15
Grade of malignancy
11 7
22 6
38 2 3
Primary site
Retroperitoneum 4 11
Trunk and limbs 2 15
Uterine 2 2
Other 3 8
Table 2 Haematologic toxicity (% of patients)
NCI CTC grade
01234
Haemoglobin 4 15 62 17 2
Leucocytes 4 7 36 40 13
Granulocytes 7 4 19 21 49
Platelets 53 9 23 13 2
Table 3 Non-haematologic toxicity (% of patients)
NCI CTC grade
01234
Nausea 35 35 28 2 —
Vomiting 49 30 19 2 —
Diarrhoea 64 13 19 4 —
Anorexia 49 28 23 — —
Asthenia 11 23 53 13 —
Stomatitis 23 17 14 46 —
Oesophagitis 62 15 15 8 —
Cutaneous 81 11 8 — —
Hepatic 92 6 — 2 —
Flu-like 85 11 4 — —
Febrile neutropenia ———1 4 6
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s95% CI: 9–35%). Sensitive histotypes were leiomyosarcoma (three
out of six), fibrosarcoma (one out of two), sarcoma phyllodes (one
out of one), malignant fibrous histiocytoma (one out of four),
liposarcoma (one out of eight) and unclassified sarcoma (one out
of five). Responding leiomyosarcomas originated in the trunk,
uterus or retroperitoneum (one each). Duration of response was
30721 weeks (mean7s.d.), median time to disease progression
was 28 weeks (95% CI: 21–34 weeks) and the progression-free rate
(7s.e.) at 3 and 6 months was 6970.08 and 5670.08%,
respectively. Eventually, 27 patients left the study owing to
progressive disease and nine retired prematurely: seven because
of excessive toxicity and two to follow another therapeutic
procedures. At analysis, with a median follow-up of 35 months,
five patients were alive (two without evidence of disease), two were
lost to follow-up with active disease and 29 had died of disease.
Median overall survival was 60 weeks (95% CI: 39–81 weeks).
Pharmacokinetics
Pharmacokinetic parameters of gemcitabine and dFdU in plasma
(n¼8), and data from dFdCTP accumulation in PBMCs (n¼6) on
days 1 and 8 are presented in Table 4. Gemcitabine half-life was
12.574.31min (range 6.35–18min) and its apparent volume of
distribution was 76.35744.2l (range 24.30–156l (mean7s.d.)
(n¼6)). Gemcitabine Css was usually reached at 30min, and
plasma dFdU peaked at 90.0717.2min from start of gemcitabine
infusion. Gemcitabine parameters did not differ between days 1
and 8. AUC0 8h of dFdU was 21% lower on day 8 (gemcitabine
alone) than on day 1 (DXR preceding gemcitabine) (P¼0.02), and
the relation AUC0 8hdFdU/AUC gemcitabine was higher on day 1
(P¼0.01). With regard to dFdCTP concentration in PBMCs, Cmax
(P¼0.03), AUCinf (P¼0.03) and AUC0 8h (P¼0.04) were higher
on day 8.
AUC1 8h for DXR and DOL (mean7s.d.) were 2817122 and
1487100nMh, respectively, for gemcitabine patients, and 256761
and 142766nMh for historical controls (P¼0.60 for DXR and
P¼0.88 for DOL comparison).
DISCUSSION
This is the first study designed in ASTS to evaluate the toxicity
profile and the activity of DXR plus FDR infusion gemcitabine
delivered as first-line therapy. In the Phase I study, dose-limiting
stomatitis and neutropenia were noted in two of six patients
treated at dose level 1 and, according to the study design, this
represented the MTD and a lower dose level should have been
opened. However, we decided to include three additional patients
at dose level 1 to confirm our findings. It was considered that the
dose of gemcitabine was already low when the recommended dose
for FDR infusion was 1500mgm
 2 (weekly schedule) (Brand et al,
1997), and data from our group, subsequently published (Buesa
et al, 2004), had shown that gemcitabine 1800mgm
 2 FDR plus
DTIC 500mgm
 2, both given every 2 weeks, were well tolerated.
Because none of those three new patients had DLT, dose level 2 was
explored and the Phase I closed when two of two patients
developed DLT at this dose level.
The Phase II was conducted at DXR 60mgm
 2 on day 1 with
gemcitabine 800mgm
 2 infused over 80min on days 1 and 8 (dose
level 1), repeated every 3 weeks. This schedule was poorly
tolerated, which contrasts with the toxicity of single-agent DXR
administered at 75mgm
 2 every 3 weeks (Borden et al, 1990;
Santoro et al, 1995). In three first-line studies conducted with a
combination of gemcitabine followed by DXR in patients with
different tumour types, projected dose intensities were 10–
25mgm
 2week
 1 for DXR and 600–833mgm
 2week
 1 for
gemcitabine. Authors communicate, in general, low levels of
toxicity, with stomatitis greater than grade 2 in 14–22% of patients
and grade 4 neutropenia in 14–21% (Pe ´rez-Manga et al, 2000;
Go ´mez et al, 2001; Yang et al, 2002). Exposure to 4-epi-
doxorubicin followed by gemcitabine proved to be synergistic in
cancer cell lines grown in vitro, with a 65% increase in DNA
damage when compared with the reverse sequence or simulta-
neous administration (Zoli et al, 2004). According to this finding,
one might hypothesise that a higher DNA damage combined with a
tissue-specific sensitivity could explain the poor mucosal and
haematologic tolerance of our schedule.
This trial was accompanied by an exploratory study of the
pharmacokinetics of gemcitabine and of dFdCTP accumulation in
PBMCs. The paired comparison of data obtained on day 1 (DXR
preceding gemcitabine) and on day 8 (gemcitabine only) indicates
that DXR interferes with gemcitabine activation to dFdCTP by
PBMCs, and facilitates gemcitabine deamination (Table 4). The
lower dFdCTP synthesis on day 1 would not be secondary to a
decrease in gemcitabine membrane transport, due to the higher
gemcitabine deamination observed on day 1 and that most of
gemcitabine deamination occurs intracellularly, with plasma
cytidine deaminase activity playing a limited role (Abbruzzese
et al, 1991). It seems unlikely that the dose of gemcitabine given on
day 1 would induce an increase in PBMC deoxycytidine kinase
activity, as it has been detected in pancreatic cell lines in vitro
(Giovannetti et al, 2004). The pharmacokinetics of DXR during the
limited period studied was not affected by gemcitabine when
compared with historical controls, similar to the results of other
studies (Pe ´rez-Manga et al, 2000; Fogli et al, 2002). The
administration of gemcitabine followed by DXR would probably
not influence gemcitabine activation and perhaps could offer a
better therapeutic index than the present schedule.
The 22% remission rate detected (95% CI: 9–35%) is within the
14–25% range reported for single-agent first-line DXR delivered at
70–75mgm
 2 every 3 weeks (Brennan et al, 2001, p 1841).
Apparently, the addition of gemcitabine did not increase DXR
activity, although this could only be ascertained by a comparative
study. Our results contrast with those of the combination of
gemcitabine and docetaxel (TXT), an agent with limited activity in
ASTS (van Hoesel et al, 1994; Verweij et al, 2000). This
combination induced a 43–53% remission rate in two Phase II
studies, an efficacy that was almost limited to patients with
leiomyosarcoma of any origin (Hensley et al, 2002; Leu et al, 2004).
In our series, 50% of leiomyosarcoma patients responded to
therapy, which confirms the sensitivity of this histotype to
Table 4 Pharmacokinetics of gemcitabine and its metabolites
Day 1 Day 8 P
Gemcitabine (n¼8)
Css (mM)1 6 76.1 19.179.5 0.33
AUC (mMh) 21.177.2 20.575.4 0.80
Cl (lmin
 1) 4.771.3 4.371.3 1.00
dFdU (n¼8)
Cmax (mM) 65.3715.4 62.1712.2 0.40
AUC0–8h (mMh) 364778 286778 0.02
AUC0–8h dFdU/AUC gemcitabine 18.375.1 14.574.6 0.01
dFdCTP (n¼6)
Cmax (pmol10
 6 PBMC) 177.37117.4 2367113 0.02
AUCinf (pmolh10
 6 PBMC) 81739 141764 0.03
AUC0–8h (pmolh10
 6 PBMC) 7347370 9577262 0.04
Patients were treated with doxorubicin (60mgm
 2) immediately followed by
gemcitabine (800mgm
 2 over 80min) on day 1, and only with gemcitabine
(800mgm
 2 over 80min) on day 8. dFdU¼difluorodeoxyuridine; dFdCTP¼gem-
citabine triphosphate in peripheral blood mononuclear cells (PBMCs); Css¼concen-
tration at steady state; AUC0–8h¼area under the curve for the first 8h from start of
gemcitabine infusion; Cl¼total body clearance; Cmax¼maximum concentration;
AUCinf¼dFdCTP accumulation in PBMCs during gemcitabine infusion. Values
represent mean7s.d. P¼P-value of the Wilcoxon sign test for paired comparisons.
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sgemcitabine-containing combinations (Buesa et al, 2004). In those
studies, only gemcitabine was given on day 1, whereas on day 8
gemcitabine preceded TXT, a sequence that was synergistic in an
osteosarcoma and a breast cancer cell line (Leu et al, 2004);
however, in lung cancer cell lines, the opposite sequence was more
effective (Zoli et al, 1999). Similarly, in vitro studies have shown
that the effects of a combination of DXR and gemcitabine depend
both on the sequence of administration and on the particular cell
line studied (Chow et al, 2000; Zoli et al, 2004).
The administration of gemcitabine followed by DXR, or the
delivery of DXR on day 8, would perhaps offer a better therapeutic
index than the present schedule, which cannot be recommended
for further study.
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